109 related articles for article (PubMed ID: 19852071)
1. Dopamine transporter PET in normal aging: dopamine transporter decline and its possible role in preservation of motor function.
Troiano AR; Schulzer M; de la Fuente-Fernandez R; Mak E; McKenzie J; Sossi V; McCormick S; Ruth TJ; Stoessl AJ
Synapse; 2010 Feb; 64(2):146-51. PubMed ID: 19852071
[TBL] [Abstract][Full Text] [Related]
2. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias.
Troiano AR; de la Fuente-Fernandez R; Sossi V; Schulzer M; Mak E; Ruth TJ; Stoessl AJ
Neurology; 2009 Apr; 72(14):1211-6. PubMed ID: 19020294
[TBL] [Abstract][Full Text] [Related]
3. Age-related decline in dopamine transporter in human brain using PET with a new radioligand [¹⁸F]FE-PE2I.
Shingai Y; Tateno A; Arakawa R; Sakayori T; Kim W; Suzuki H; Okubo Y
Ann Nucl Med; 2014 Apr; 28(3):220-6. PubMed ID: 24385293
[TBL] [Abstract][Full Text] [Related]
4. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.
Adams JR; van Netten H; Schulzer M; Mak E; Mckenzie J; Strongosky A; Sossi V; Ruth TJ; Lee CS; Farrer M; Gasser T; Uitti RJ; Calne DB; Wszolek ZK; Stoessl AJ
Brain; 2005 Dec; 128(Pt 12):2777-85. PubMed ID: 16081470
[TBL] [Abstract][Full Text] [Related]
5. Age-related loss of olfactory sensitivity: association to dopamine transporter binding in putamen.
Larsson M; Farde L; Hummel T; Witt M; Lindroth NE; Bäckman L
Neuroscience; 2009 Jun; 161(2):422-6. PubMed ID: 19348872
[TBL] [Abstract][Full Text] [Related]
6. VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET.
De La Fuente-Fernández R; Furtado S; Guttman M; Furukawa Y; Lee CS; Calne DB; Ruth TJ; Stoessl AJ
Synapse; 2003 Jul; 49(1):20-8. PubMed ID: 12710012
[TBL] [Abstract][Full Text] [Related]
7. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
Kilbourn MR; Kuszpit K; Sherman P
Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
[TBL] [Abstract][Full Text] [Related]
8. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study.
Sossi V; de la Fuente-Fernández R; Schulzer M; Troiano AR; Ruth TJ; Stoessl AJ
Ann Neurol; 2007 Nov; 62(5):468-74. PubMed ID: 17886297
[TBL] [Abstract][Full Text] [Related]
9. Age and severity of nigrostriatal damage at onset of Parkinson's disease.
De La Fuente-Fernández R; Lim AS; Sossi V; Adam MJ; Ruth TJ; Calne DB; Stoessl AJ; Lee CS
Synapse; 2003 Feb; 47(2):152-8. PubMed ID: 12454953
[TBL] [Abstract][Full Text] [Related]
10. Dopamine transporters decrease with age.
Volkow ND; Ding YS; Fowler JS; Wang GJ; Logan J; Gatley SJ; Hitzemann R; Smith G; Fields SD; Gur R
J Nucl Med; 1996 Apr; 37(4):554-9. PubMed ID: 8691238
[TBL] [Abstract][Full Text] [Related]
11. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers.
Volkow ND; Chang L; Wang GJ; Fowler JS; Leonido-Yee M; Franceschi D; Sedler MJ; Gatley SJ; Hitzemann R; Ding YS; Logan J; Wong C; Miller EN
Am J Psychiatry; 2001 Mar; 158(3):377-82. PubMed ID: 11229977
[TBL] [Abstract][Full Text] [Related]
12. The role of the striatal dopamine transporter in cognitive aging.
Erixon-Lindroth N; Farde L; Wahlin TB; Sovago J; Halldin C; Bäckman L
Psychiatry Res; 2005 Jan; 138(1):1-12. PubMed ID: 15708296
[TBL] [Abstract][Full Text] [Related]
13. Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker?
Boileau I; Rusjan P; Houle S; Wilkins D; Tong J; Selby P; Guttman M; Saint-Cyr JA; Wilson AA; Kish SJ
J Neurosci; 2008 Sep; 28(39):9850-6. PubMed ID: 18815269
[TBL] [Abstract][Full Text] [Related]
14. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133.
Okamura N; Villemagne VL; Drago J; Pejoska S; Dhamija RK; Mulligan RS; Ellis JR; Ackermann U; O'Keefe G; Jones G; Kung HF; Pontecorvo MJ; Skovronsky D; Rowe CC
J Nucl Med; 2010 Feb; 51(2):223-8. PubMed ID: 20080893
[TBL] [Abstract][Full Text] [Related]
15. Dopamine turnover increases in asymptomatic LRRK2 mutations carriers.
Sossi V; de la Fuente-Fernández R; Nandhagopal R; Schulzer M; McKenzie J; Ruth TJ; Aasly JO; Farrer MJ; Wszolek ZK; Stoessl JA
Mov Disord; 2010 Dec; 25(16):2717-23. PubMed ID: 20939082
[TBL] [Abstract][Full Text] [Related]
16. Age-dependent decline of dopamine D1 receptors in human brain: a PET study.
Wang Y; Chan GL; Holden JE; Dobko T; Mak E; Schulzer M; Huser JM; Snow BJ; Ruth TJ; Calne DB; Stoessl AJ
Synapse; 1998 Sep; 30(1):56-61. PubMed ID: 9704881
[TBL] [Abstract][Full Text] [Related]
17. [(11)C]d-threo-methylphenidate PET in patients with Parkinson's disease and essential tremor.
Breit S; Reimold M; Reischl G; Klockgether T; Wüllner U
J Neural Transm (Vienna); 2006 Feb; 113(2):187-93. PubMed ID: 15959851
[TBL] [Abstract][Full Text] [Related]
18. Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: positron emission tomographic studies.
Koochesfahani KM; de la Fuente-Fernández R; Sossi V; Schulzer M; Yatham LN; Ruth TJ; Blinder S; Stoessl AJ
Mov Disord; 2006 Jul; 21(7):970-5. PubMed ID: 16570297
[TBL] [Abstract][Full Text] [Related]
19. Regional analysis of age-related decline in dopamine transporters and dopamine D2-like receptors in human striatum.
Ishibashi K; Ishii K; Oda K; Kawasaki K; Mizusawa H; Ishiwata K
Synapse; 2009 Apr; 63(4):282-90. PubMed ID: 19116949
[TBL] [Abstract][Full Text] [Related]
20. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging.
Frey KA; Koeppe RA; Kilbourn MR; Vander Borght TM; Albin RL; Gilman S; Kuhl DE
Ann Neurol; 1996 Dec; 40(6):873-84. PubMed ID: 9007092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
